Positron Emission Tomography with [18F]ROStrace Reveals Progressive Elevations in Oxidative Stress in a Mouse Model of Alpha-Synucleinopathy

The synucleinopathies are a diverse group of neurodegenerative disorders characterized by the accumulation of aggregated alpha-synuclein (aSyn) in vulnerable populations of brain cells. Oxidative stress is both a cause and a consequence of aSyn aggregation in the synucleinopathies; however, noninvasive methods for detecting oxidative stress in living animals have proven elusive. In this study, we used the reactive oxygen species (ROS)-sensitive positron emission tomography (PET) radiotracer [18F]ROStrace to detect increases in oxidative stress in the widely-used A53T mouse model of synucleinopathy. A53T-specific elevations in [18F]ROStrace signal emerged at a relatively early age (6–8 months) and became more widespread within the brain over time, a pattern which paralleled the progressive development of aSyn pathology and oxidative damage in A53T brain tissue. Systemic administration of lipopolysaccharide (LPS) also caused rapid and long-lasting elevations in [18F]ROStrace signal in A53T mice, suggesting that chronic, aSyn-associated oxidative stress may render these animals more vulnerable to further inflammatory insult. Collectively, these results provide novel evidence that oxidative stress is an early and chronic process during the development of synucleinopathy and suggest that PET imaging with [18F]ROStrace holds promise as a means of detecting aSyn-associated oxidative stress noninvasively.

[1]  C. Lee,et al.  Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson's disease. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  D. D. Di Monte,et al.  Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading , 2022, Science advances.

[3]  Ji Youn Lee,et al.  [18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer’s disease pathology in APP/PS1 mice , 2022, bioRxiv.

[4]  T. Weissman,et al.  Phosphorylation of the aggregate-forming protein alpha-synuclein on serine-129 inhibits its DNA-bending properties , 2021, The Journal of biological chemistry.

[5]  C. Dobson,et al.  The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells , 2021, Nature Communications.

[6]  Pablo Aguiar,et al.  Intensity normalization methods in brain FDG-PET quantification , 2020, NeuroImage.

[7]  Meir Schechter,et al.  α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate , 2020, The Journal of Biological Chemistry.

[8]  S. Duchesne,et al.  Selection of the optimal intensity normalization region for FDG-PET studies of normal aging and Alzheimer’s disease , 2020, Scientific Reports.

[9]  Fei Zou,et al.  Poly (ADP‐ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α‐synuclein degradation via transcription factor EB‐dependent autophagy in mutant α‐synucleinA53T model of Parkinson's disease , 2020, Aging cell.

[10]  E. Masliah,et al.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment. , 2019, Free radical biology & medicine.

[11]  Nikhil Panicker,et al.  Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease , 2019, Neuron.

[12]  D. D. Di Monte,et al.  Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. , 2019, The Journal of clinical investigation.

[13]  T. Weissman,et al.  Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders , 2019, Scientific Reports.

[14]  Shu-Ying Liu,et al.  Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease. , 2018, Food & function.

[15]  J. Troncoso,et al.  Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease , 2018, Science.

[16]  K. Schroder,et al.  Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice , 2018, Science Translational Medicine.

[17]  N. Forsyth,et al.  Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors , 2018, Front. Cell Dev. Biol..

[18]  T. Südhof,et al.  Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.

[19]  O. El‐Agnaf,et al.  Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice , 2017, Scientific Reports.

[20]  M. Mintun,et al.  Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation , 2017, ACS chemical neuroscience.

[21]  J. Rinne,et al.  Brain energy metabolism and neuroinflammation in ageing APP/PS1-21 mice using longitudinal 18F-FDG and 18F-DPA-714 PET imaging , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  V. Lee,et al.  Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production , 2017, Cellular and Molecular Life Sciences.

[23]  J. Pu,et al.  Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease , 2017, Journal of movement disorders.

[24]  T. Myöhänen,et al.  Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector–Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain , 2016, The Journal of Neuroscience.

[25]  N. Albert,et al.  Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study , 2016, The Journal of Nuclear Medicine.

[26]  W. Poewe,et al.  The Concept of Prodromal Parkinson’s Disease , 2015, Journal of Parkinson's disease.

[27]  Syed F. Ali,et al.  Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models. , 2015, Brain : a journal of neurology.

[28]  Vivek K Unni,et al.  Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism , 2015, Cell reports.

[29]  B. Harvey,et al.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse , 2014, Neurobiology of Disease.

[30]  S. Chandra,et al.  Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis , 2014, The Journal of Neuroscience.

[31]  M. Mintun,et al.  Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. , 2014, Organic & biomolecular chemistry.

[32]  N. Chandel,et al.  ROS Function in Redox Signaling and Oxidative Stress , 2014, Current Biology.

[33]  Z. Berger,et al.  Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease , 2013, PloS one.

[34]  Jiajie Diao,et al.  Properties of native brain α-synuclein , 2013, Nature.

[35]  R. Parsey,et al.  Reference Region Approaches in PET: a Comparative Study on Multiple Radioligands , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Axel T Brunger,et al.  Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2 , 2013, eLife.

[37]  Rafael Radi,et al.  Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects. , 2013, Accounts of chemical research.

[38]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[39]  E. Masliah,et al.  Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. , 2012, Human molecular genetics.

[40]  A. Negro,et al.  α-Synuclein Controls Mitochondrial Calcium Homeostasis by Enhancing Endoplasmic Reticulum-Mitochondria Interactions* , 2012, The Journal of Biological Chemistry.

[41]  Bernard Schneider,et al.  α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer* , 2012, The Journal of Biological Chemistry.

[42]  J. Franklin,et al.  The Mitochondria-Targeted Antioxidant MitoQ Prevents Loss of Spatial Memory Retention and Early Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[43]  Jau-Shyong Hong,et al.  Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease , 2011, Environmental health perspectives.

[44]  J. Andersen,et al.  Synergistic effects of environmental risk factors and gene mutations in Parkinson’s disease accelerate age‐related neurodegeneration , 2010, Journal of neurochemistry.

[45]  S. Kalivendi,et al.  Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. , 2010, Free radical biology & medicine.

[46]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[47]  A. Sidhu,et al.  Mice expressing the A53T mutant form of human alpha‐synuclein exhibit hyperactivity and reduced anxiety‐like behavior , 2010, Journal of neuroscience research.

[48]  Xiaohui Xu,et al.  Nitrated α-Synuclein Induces the Loss of Dopaminergic Neurons in the Substantia Nigra of Rats , 2010, PloS one.

[49]  Ad Bax,et al.  Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. , 2009, Journal of molecular biology.

[50]  L. Forno,et al.  Pathologic Modifications of &agr;-Synuclein in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Treated Squirrel Monkeys , 2008, Journal of neuropathology and experimental neurology.

[51]  N. Avadhani,et al.  Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.

[52]  H. Kato,et al.  Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson’s disease , 2008, Metabolic Brain Disease.

[53]  M. Parihar,et al.  Mitochondrial association of alpha-synuclein causes oxidative stress , 2008, Cellular and Molecular Life Sciences.

[54]  H. Gendelman,et al.  Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.

[55]  Joanna S. Fowler,et al.  A novel approach for imaging brain–behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator , 2007, NeuroImage.

[56]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[57]  H. Gendelman,et al.  Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson’s disease , 2007, Journal of neurochemistry.

[58]  Leonidas Stefanis,et al.  α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis , 2006, The Journal of Neuroscience.

[59]  R. Deacon Assessing nest building in mice , 2006, Nature Protocols.

[60]  Hongtao Zhao,et al.  Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[63]  Rafael Radi,et al.  Nitric oxide, oxidants, and protein tyrosine nitration , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Przedborski,et al.  Nitric Oxide and Reactive Oxygen Species in Parkinson's Disease , 2003, IUBMB life.

[65]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[66]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[67]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[69]  Virginia M. Y. Lee,et al.  Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.

[70]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[71]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[72]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[73]  H. Ischiropoulos Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. , 1998, Archives of biochemistry and biophysics.

[74]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[75]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[76]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[77]  Guy B. Williams,et al.  SPMMouse: A new toolbox for SPM in the animal brain , 2009 .

[78]  Jun Guo,et al.  Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells , 2007, Cellular and Molecular Neurobiology.